The Effect of Diet Supplementation with Pomegranate and Bitter Melon on Lipidomic Profile of Serum and Cancerous Tissues of Rats with Mammary Tumours.
None
CLA
CLnA
HETE
HODE
LOX
malondialdehyde
mammary tumour
oxysterol
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
17 Mar 2020
17 Mar 2020
Historique:
received:
18
02
2020
revised:
15
03
2020
accepted:
16
03
2020
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
21
3
2020
Statut:
epublish
Résumé
The aim of this study was to present overall lipid profile of organisms with ongoing neoplastic process and applied diet supplementation with pomegranate seed oil (PSO) and bitter melon extract (BME). The following were quantified in serum and cancerous tissues of rats suffering from mammary tumours: fatty acids, conjugated fatty acids and sterols, their oxidised metabolites (malondialdehyde and oxysterols) and lipoxygenase (LOX) metabolites of polyunsaturated fatty acids. The obtained results indicate that abnormalities in lipid metabolism accompany neoplastic process. These differences concern all classes of lipids and most pathways of their transformation, with the special emphasis on lipid peroxidation and LOX-mediated metabolism. Cancer process appears to be so detrimental that it may conceal positive influence of dietary modifications. The lack of anticarcinogenic properties of PSO and BME in this model may be due to their antioxidant properties or elevated levels of conjugated linoleic acids (CLA), which change CLA isomer activity from anti- to pro-tumorigenic. As CLA are the product of conjugated linolenic acids (CLnA) endogenous metabolism, high CLA levels may be explained by applied diet enrichment.
Identifiants
pubmed: 32192197
pii: antiox9030243
doi: 10.3390/antiox9030243
pmc: PMC7139718
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2018/02/X/NZ9/01770
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Cancer Prev. 2016 Dec;21(4):209-215
pubmed: 28053954
Eur J Radiol. 2019 Jul;116:205-211
pubmed: 31153566
Cancer Commun (Lond). 2018 May 21;38(1):27
pubmed: 29784041
Prostaglandins Other Lipid Mediat. 2019 Jun;142:33-45
pubmed: 30928411
BMC Cancer. 2014 Feb 18;14:105
pubmed: 24548731
Mol Nutr Food Res. 2015 Sep;59(9):1780-90
pubmed: 26081224
World J Biol Chem. 2012 Aug 26;3(8):167-74
pubmed: 22937213
Cancer Lett. 2018 Oct 28;435:92-100
pubmed: 30102953
Prog Lipid Res. 2013 Oct;52(4):585-9
pubmed: 24001676
Nutrients. 2018 Dec 01;10(12):
pubmed: 30513730
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
J Leukoc Biol. 2015 Dec;98(6):897-912
pubmed: 26216937
Int J Cancer. 2002 Mar 1;98(1):78-83
pubmed: 11857389
Cancer Lett. 2017 Aug 10;401:39-45
pubmed: 28527945
Lipids Health Dis. 2010 Nov 02;9:126
pubmed: 21044306
Prostaglandins Other Lipid Mediat. 2015 Jan-Mar;116-117:10-8
pubmed: 25448730
Breast. 2019 Jun;45:113-117
pubmed: 30959386
Lipids Health Dis. 2019 Jan 26;18(1):29
pubmed: 30684960
Biochim Biophys Acta. 2014 Nov;1842(11):2230-6
pubmed: 25201082
Prostaglandins Other Lipid Mediat. 2016 Nov;126:29-37
pubmed: 27418544
Nutrients. 2019 Feb 11;11(2):
pubmed: 30754681
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2251-8
pubmed: 21727037
Prostaglandins Other Lipid Mediat. 2020 Apr;147:106381
pubmed: 31698146
Trends Endocrinol Metab. 2017 Jul;28(7):485-496
pubmed: 28410994
Prostaglandins Leukot Essent Fatty Acids. 2017 Nov;126:1-8
pubmed: 29031386
Molecules. 2018 Aug 03;23(8):
pubmed: 30081476
J Natl Cancer Inst. 1995 Apr 19;87(8):587-92
pubmed: 7752256
J Steroid Biochem Mol Biol. 2017 May;169:39-45
pubmed: 26921766
FASEB J. 2001 Sep;15(11):2007-9
pubmed: 11511519
Nutr Hosp. 2016 Nov 29;33(6):1354-1360
pubmed: 28000465
Postepy Hig Med Dosw (Online). 2014 Nov 06;68:1238-50
pubmed: 25380206
J Pharm Biomed Anal. 2006 Jun 16;41(4):1317-24
pubmed: 16621414
Prostaglandins Other Lipid Mediat. 2017 Jul;131:9-16
pubmed: 28559164
Lipids. 2001 Feb;36(2):139-43
pubmed: 11269694
Prostate. 2014 May;74(6):618-27
pubmed: 24435810
Asian Pac J Cancer Prev. 2019 May 25;20(5):1321-1327
pubmed: 31127884
Metabolism. 2013 Aug;62(8):1107-13
pubmed: 23522836
J Trace Elem Med Biol. 2020 May;59:126450
pubmed: 31931255
Br J Cancer. 2011 Jul 12;105(2):263-71
pubmed: 21629247
J Cell Physiol. 2016 Oct;231(10):2128-41
pubmed: 26844415
Exp Mol Med. 2018 Sep 21;50(9):127
pubmed: 30242145
Nutrients. 2019 May 28;11(6):
pubmed: 31141912
Am J Cancer Res. 2018 May 01;8(5):778-791
pubmed: 29888102
Int J Nanomedicine. 2019 Apr 23;14:2809-2828
pubmed: 31114196
Prostaglandins Leukot Essent Fatty Acids. 2016 Mar;106:1-10
pubmed: 26926361
FASEB J. 2001 Nov;15(13):2326-36
pubmed: 11689458
Acta Pol Pharm. 2014 Sep-Oct;71(5):747-61
pubmed: 25362803
Postepy Hig Med Dosw (Online). 2013 Jan 11;67:6-14
pubmed: 23475478
Lipids. 2005 Feb;40(2):137-45
pubmed: 15884761
Acta Pol Pharm. 2016 Mar-Apr;73(2):315-27
pubmed: 27180424
ISRN Oncol. 2012;2012:137289
pubmed: 23119185
Nutr Cancer. 2015;67(1):145-55
pubmed: 25412117
PLoS One. 2019 Jun 26;14(6):e0218246
pubmed: 31242216
Breast Cancer Res. 2007;9(1):201
pubmed: 17224037